Letybo vs Relfydess

The clinical landscape of wrinkle reduction treatment is undergoing a structural disruption. For prospective patients, the internal conflict between psychological vitality and the physical manifestation of aging often centers on the hyperfunctional contraction of facial muscles. The traditional aesthetic market has historically offered a confusing array of identical-sounding botulinum toxin type A (BoNT-A) products. Today, the choice is no longer just about smoothing glabellar lines—it is about selecting the precise biochemical delivery system that matches a patient’s exact anatomical requirements, metabolic rate, and schedule.

Call our reception today to book your consultation.

077 4747 4755

The introduction of Letybo and Relfydess forces a reevaluation of standard neuromodulator protocols. One masters the traditional high-purity powder format, while the other introduces a logistical paradigm shift as a ready-to-use liquid formulation.

The Inciting Incident of Facial Aging

Biological aging is fundamentally mechanical. Decades of repetitive muscle contractions—frowning, squinting, and expressing—create microscopic stress fractures in the dermal collagen matrix. Over time, the corrugator supercilii and procerus muscles become hypertonic, locked in a baseline state of tension that visually projects anger, fatigue, or stress even when the face is at rest.

This disconnect is the primary catalyst driving patients to seek aesthetic treatments. The objective is not to “freeze” the face—a common fear stemming from outdated, poorly diffused injection techniques—but to selectively block the presynaptic release of acetylcholine at the neuromuscular junction, restoring a baseline of dynamic harmony. Want to read more about aesthetic medicine procedures and anti wrinkle injections? Just Click.

Dr Joanna Kisiel
Radiology Consultant

Enter your phone number and our consultant will call you back …

The Crisis of Choice in Formulation Architecture

Navigating FDA-approved neurotoxins requires understanding that the vehicle delivering the active molecule is as critical as the molecule itself.

The Refined Standard: Letybo (letibotulinumtoxinA-wlbg)

Developed by Hugel and FDA-approved for the U.S. market on February 29, 2024, Letybo represents the optimization of classic neuromodulator mechanics. It utilizes the traditional 900 kDa protein complex structure. Letybo arrives at the clinic as a lyophilized (freeze-dried) powder that the practitioner must reconstitute with sterile saline immediately prior to injection.

Its clinical value lies in its exceptional purity and highly predictable diffusion radius. Practitioners accustomed to adjusting dilution ratios for specialized off-label treatments—such as masseter hypertrophy (jaw slimming) or advanced facial contouring—can easily adapt Letybo’s powder format to their specific procedural workflow.

The Liquid Breakthrough: Relfydess (relabotulinumtoxinA)

Relfydess, engineered by Galderma, fundamentally changes the preparation protocol by eliminating the lyophilization process entirely. Utilizing proprietary PEARL™ Technology, it is the first and only ready-to-use liquid botulinum toxin.

For the patient, this internal clinical shift offers massive external benefits. Reconstituting powder introduces the risk of human error—specifically dilution inconsistencies that can lead to asymmetrical results or a broader diffusion field that inadvertently paralyses adjacent muscles, causing the dreaded “frozen face” or eyebrow ptosis. Relfydess eliminates reconstitution, ensuring an exact, homogenous dose and volume in every single syringe. Furthermore, it strips away the accessory proteins, leaving a complex-free, highly active molecule.

Pharmacological Profile	Letybo (letibotulinumtoxinA-wlbg)	Relfydess (relabotulinumtoxinA)
Formulation State	Lyophilized powder	Ready-to-use liquid
Molecular Complex	900 kDa (requires dissociation)	Complex-free (preserves molecule integrity)
U.S. Regulatory Status	FDA Approved (Feb 29, 2024)	FDA CRL Issued (July 2026) for manufacturing
Global Regulatory Status	CE Marked, >9,000 US practices	Approved in 33 markets (EU, UK, AU, Asia)
Clinical Onset	Visible at 2–5 days	Up to 39% of patients observe effects on Day 1
Efficacy Duration	3–4 months (Standard)	Up to 6 months (Extended)
Primary Indication	Moderate-to-severe glabellar lines	Glabellar and lateral canthal lines

Clinical Kinetics: Onset, Duration, and Recovery

The metrics of success for any aesthetic treatment are defined by how quickly it activates, how precisely it stays within the target zone, and how long the paralysis lasts before the neuromuscular junction generates new axonal sprouts.

Speed of Activation:

• Letybo: Patients typically report visible softening of dynamic wrinkles within 2 to 5 days, reaching peak clinical efficacy at approximately 30 days.
• Relfydess: Phase III READY clinical trials demonstrated unprecedented onset speed. Up to 39% of patients reported visible neurotoxin onset on Day 1.

Neuromodulator Longevity:

• Letybo: Delivers a reliable, industry-standard duration of 3 to 4 months. This makes it highly suitable for patients who prefer the traditional quarterly maintenance schedule.
• Relfydess: Sustains chemical denervation for up to 6 months in up to 75% of patients for both frown lines and crow’s feet. This prolonged receptor binding cuts required clinic visits in half.

Recovery Profile:

Both formulations share an identical, virtually non-existent recovery timeline. Post-injection localized erythema (redness) and mild edema (swelling) typically dissipate within 15 to 45 minutes. Patients must avoid strenuous activity, high heat, and manual manipulation of the face for 24 hours to prevent unintended physical migration of the toxin outside the targeted anatomical field.

Enter your phone number and our consultant will call you back …

Regulatory Realities and Hidden Trade-Offs

Absolute transparency requires acknowledging the current regulatory availability of both drugs.

Letybo has fully penetrated the United States aesthetic market. Since its commercial launch in March 2025, it has been integrated into over 9,000 U.S. practices. It is highly accessible and clinically proven.

Relfydess presents a more complex global footprint. While it is approved in 33 international markets—including the European Union (August 2024), the United Kingdom, and Australia—its U.S. rollout has faced delays. In July 2026, the U.S. FDA issued a Complete Response Letter (CRL) regarding Galderma’s Biologics License Application. Crucially, this delay was strictly tied to manufacturing site inspection observations and analytical method optimization, not the safety or clinical efficacy of the drug itself. U.S. patients must currently wait for FDA resolution before accessing Relfydess, while international patients are already benefiting from its Day 1 onset.

Strategic Patient Selection

The choice between LetibotulinumtoxinA and RelabotulinumtoxinA comes down to prioritizing either established adaptability or next-generation longevity.
1. The Letybo Profile: Ideal for patients who value a highly purified, cost-effective formulation with a standard 3-to-4-month lifespan. It is the pragmatic choice for those already satisfied with the traditional cadence of aesthetic treatments but seeking an alternative to legacy brands.
2. The Relfydess Profile: Engineered for the demanding, time-poor patient. It is designed for those who require immediate, Day 1 onset for an upcoming event, or those seeking to extend their treatment intervals to a twice-yearly schedule (6-month duration). It provides unparalleled peace of mind regarding dilution accuracy.

By selecting the correct molecular tool for the specific anatomical task, patients transcend the fear of artificial outcomes. The result is the preservation of authentic expression, free from the hyperfunctional tension that masks their true vitality.

Aesthetic Medicine Clinic London Maple Cross, Denham, Rickmansworth

Find a treatment suitable for you … Type in your concern…

Which Wrinkle-Smoothing Treatment Is Right for You?

Choosing the right anti-wrinkle treatment comes down to your lifestyle, your schedule, and how quickly you want to see results. While both Letybo and Relfydess safely relax facial tension to give you a smooth, refreshed appearance, they work on two different timelines:

Choose Letybo for the Reliable Classic Routine: If you want a tried-and-tested option that delivers natural, dependable smoothing at a great value, Letybo is a perfect fit. It kicks in within 2 to 5 days, keeps skin smooth for 3 to 4 months, and fits right into a standard quarterly self-care routine.

Choose Relfydess for Super-Fast Results and Longer Lasting Power: If you have a busy schedule, an upcoming event, or prefer fewer appointments, Relfydess is the ultimate choice. As a ready-to-use liquid treatment, it can show visible results in as little as 24 hours and lasts up to 6 full months—meaning you only need to visit the clinic twice a year.

Take the Guesswork Out of Your Aesthetic Care

You don’t have to decide alone. Every face is anatomically unique, and our expert clinical team is here to tailor the perfect treatment plan for your specific goals, budget, and facial structure.

Call our Maple Cross clinic today at 07747474755 to book your consultation, and take the first step toward a smoother, refreshed, and completely natural look.

Price List

Contact data

London:
42 Denham Way,
Maple Cross, Rickmansworth
WD3 9SP

phone 07747 474755

Opening hours:

Mon – Sat 11:00 – 17:00

Letybo vs Relfydess